Evidence
- barete_2015_cohort_long-term-efficacy-and-safety-of-cladribine-2-cda-in-adult-patients-with-mastocytosis
- broesby-olsen_2018_cohort_omalizumab-prevents-anaphylaxis-and-improves-symptoms-in-systemic-mastocytosis
- gotlib_2016_cohort_efficacy-and-safety-of-midostaurin-in-advanced-systemic-mastocytosis
- kluin-nelemans_2003_cohort_cladribine-therapy-for-systemic-mastocytosis
- lemal_2019_cohort_omalizumab-therapy-for-mast-cell-mediator-symptoms-in-patients-with-ism-cm-mmas-and-mcas
- lim_2009_cohort_cytorreductive-therapy-in-108-adults-with-systemic-mastocytosis-outcome-analysis-and-response-prediction-during-treatment-with-interferon-alpha-hydroxyurea-imatinib-mesylate-or-2-chlorodeoxyadenosine
- lim_2009_cohort_cytorreductive-therapy-in-108-adults-with-systemic-mastocytosis-outcome-analysis-and-response-prediction-during-treatment-with-interferon-alpha-hydroxyurea-imatinib-mesylate-or-2-chlorodeoxyadenosine
- moraly_0000_cohort_rapamycin-for-mastocytosis
- pagano_2008_cohort_advanced-mast-cell-disease-an-italian-hematological-multicenter-experience
- ustun_2014_cohort_hematopoietic-stem-cell-transplantation-for-advanced-systemic-mastocytosis
- vega-ruiz_2009_cohort_phase-ii-study-of-imatinib-mesylate-as-therapy-for-patients-with-systemic-mastocytosis
- verstovsek_2008_cohort_phase-ii-study-of-dasatinib-in-philadelphia-chromosome-negative-acute-and-chronic-myeloid-diseases-including-systemic-mastocytosis